Is Nuclear Medicine Becoming Next Big Breakthrough in Oncology Treatment? Danielle Meyrick

Update: 2025-09-19

Description

If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes.

This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover:

Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today.
From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style.
What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures.
The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum.
What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector.

If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Danielle Meyrick

Co-Founder + Director At EPIC Theranostiocs

LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/

Lawrence Rose